Cargando…

Angiogenesis in rheumatoid arthritis

CHAPTER SUMMARY: The expansion of the synovial lining of joints in rheumatoid arthritis (RA) and the subsequent invasion by the pannus of underlying cartilage and bone necessitate an increase in the vascular supply to the synovium, to cope with the increased requirement for oxygen and nutrients. The...

Descripción completa

Detalles Bibliográficos
Autor principal: Paleolog, Ewa M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2002
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3240151/
https://www.ncbi.nlm.nih.gov/pubmed/12110126
http://dx.doi.org/10.1186/ar575
_version_ 1782219349384232960
author Paleolog, Ewa M
author_facet Paleolog, Ewa M
author_sort Paleolog, Ewa M
collection PubMed
description CHAPTER SUMMARY: The expansion of the synovial lining of joints in rheumatoid arthritis (RA) and the subsequent invasion by the pannus of underlying cartilage and bone necessitate an increase in the vascular supply to the synovium, to cope with the increased requirement for oxygen and nutrients. The formation of new blood vessels – termed 'angiogenesis' – is now recognised as a key event in the formation and maintenance of the pannus in RA. This pannus is highly vascularised, suggesting that targeting blood vessels in RA may be an effective future therapeutic strategy. Disruption of the formation of new blood vessels would not only prevent delivery of nutrients to the inflammatory site, but could also lead to vessel regression and possibly reversal of disease. Although many proangiogenic factors are expressed in the synovium in RA, the potent proangiogenic cytokine vascular endothelial growth factor (VEGF) has been shown to a have a central involvement in the angiogenic process in RA. The additional activity of VEGF as a vascular permeability factor may also increase oedema and hence joint swelling in RA. Several studies have shown that targeting angiogenesis in animal models of arthritis ameliorates disease. Our own study showed that inhibition of VEGF activity in murine collagen-induced arthritis, using a soluble VEGF receptor, reduced disease severity, paw swelling, and joint destruction. Although no clinical trials of anti-angiogenic therapy in RA have been reported to date, the blockade of angiogenesis – and especially of VEGF – appears to be a promising avenue for the future treatment of RA.
format Online
Article
Text
id pubmed-3240151
institution National Center for Biotechnology Information
language English
publishDate 2002
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-32401512011-12-16 Angiogenesis in rheumatoid arthritis Paleolog, Ewa M Arthritis Res Review CHAPTER SUMMARY: The expansion of the synovial lining of joints in rheumatoid arthritis (RA) and the subsequent invasion by the pannus of underlying cartilage and bone necessitate an increase in the vascular supply to the synovium, to cope with the increased requirement for oxygen and nutrients. The formation of new blood vessels – termed 'angiogenesis' – is now recognised as a key event in the formation and maintenance of the pannus in RA. This pannus is highly vascularised, suggesting that targeting blood vessels in RA may be an effective future therapeutic strategy. Disruption of the formation of new blood vessels would not only prevent delivery of nutrients to the inflammatory site, but could also lead to vessel regression and possibly reversal of disease. Although many proangiogenic factors are expressed in the synovium in RA, the potent proangiogenic cytokine vascular endothelial growth factor (VEGF) has been shown to a have a central involvement in the angiogenic process in RA. The additional activity of VEGF as a vascular permeability factor may also increase oedema and hence joint swelling in RA. Several studies have shown that targeting angiogenesis in animal models of arthritis ameliorates disease. Our own study showed that inhibition of VEGF activity in murine collagen-induced arthritis, using a soluble VEGF receptor, reduced disease severity, paw swelling, and joint destruction. Although no clinical trials of anti-angiogenic therapy in RA have been reported to date, the blockade of angiogenesis – and especially of VEGF – appears to be a promising avenue for the future treatment of RA. BioMed Central 2002 2002-05-09 /pmc/articles/PMC3240151/ /pubmed/12110126 http://dx.doi.org/10.1186/ar575 Text en Copyright ©2002 BioMed Central Ltd
spellingShingle Review
Paleolog, Ewa M
Angiogenesis in rheumatoid arthritis
title Angiogenesis in rheumatoid arthritis
title_full Angiogenesis in rheumatoid arthritis
title_fullStr Angiogenesis in rheumatoid arthritis
title_full_unstemmed Angiogenesis in rheumatoid arthritis
title_short Angiogenesis in rheumatoid arthritis
title_sort angiogenesis in rheumatoid arthritis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3240151/
https://www.ncbi.nlm.nih.gov/pubmed/12110126
http://dx.doi.org/10.1186/ar575
work_keys_str_mv AT paleologewam angiogenesisinrheumatoidarthritis